Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites

Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two new U.S. sites.

The new facilities are located at Indiana’s LEAP Lebanon Innovation and Research District in Boone County.

David A. Ricks, Lilly’s chair and CEO, said: “These new sites will add capacity in support of our growing pipeline of innovative medicines, while also creating more high-tech jobs for Hoosiers. We are pleased to be a founding investor at the LEAP Lebanon Innovation District.”

Over the past eight years, Lilly has delivered 17 new medicines, including tirzepatide (approved by the U.S. Food and Drug Administration as Mounjaro) for the treatment of type 2 diabetes, and aims to introduce four potential new medicines in the next two years. The company said the new sites will support increased demand for its existing products.

The proposed project is expected to create up to 500 new jobs, with an additional four indirect jobs for every Lilly position created. An estimated 1,500 construction jobs will be required while the facilities are being built.

The post Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.


About the Author: Biotech Today

You might like